COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial (CHAT Pilot)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01798602
Recruitment Status : Terminated (H1N1 pandemic concluded)
First Posted : February 26, 2013
Last Update Posted : February 26, 2013
Canadian Institutes of Health Research (CIHR)
The Physicians' Services Incorporated Foundation
Public Health Agency of Canada (PHAC)
Information provided by (Responsible Party):
Canadian Critical Care Trials Group

Brief Summary:
The CHAT Pilot Trial is designed to compare rosuvastatin against placebo in patients with suspected H1N1. The pilot study will assess the feasibility of our clinical protocols, and study procedures.

Condition or disease Intervention/treatment Phase
H1N1 Influenza Drug: Rosuvastatin or identical placebo Drug: Placebo Phase 2

Detailed Description:
This trial is a pilot study to assess the feasibility and acceptability of a double blind randomized controlled trial (RCT) evaluating the efficacy of rosuvastatin as adjuvant therapy for H1N1 influenza

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial
Study Start Date : December 2009
Actual Primary Completion Date : May 2010
Actual Study Completion Date : August 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Rosuvastatin

Rosuvastatin 40 mg via nasogastric tube then 20 mg po or via nasogastric tube daily for 14 days or until hospital discharge Placebo is identical capsule with no active drug

Both are crushed for administration

Drug: Rosuvastatin or identical placebo
Tablet crushed for administration via feeding tube
Other Names:
  • Crestor
  • Placebo

Placebo Comparator: Placebo
Identical drug vehicle with no active agent
Drug: Placebo
Identical placebo for rosuvastatin

Primary Outcome Measures :
  1. Proportion of eligible patients enrolled in the CHAT study [ Time Frame: Over 6 month period or during H1N1 pandemic ]
    This was a pilot study whose primary goal was to evaluate the feasibility of patient recruitment during an emerging pandemic

Secondary Outcome Measures :
  1. Adherence to the medication administration regimen as outlined in the study protocol. [ Time Frame: 2 weeks ]
  2. Proportion of completed primary and secondary endpoints for the planned full CHAT trial that are collected. [ Time Frame: 6 months ]
  3. The number of study withdrawals due to administration of open label statins and withdrawals of consent. [ Time Frame: Up to 28 days or until hospital discharge ]
  4. Recruitment rates by consent model. [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Critically ill adult patients > 16 years of age admitted to an adult ICU for any reason with suspected, probable or confirmed novel swine origin influenza A/H1N1 infection
  • Requiring mechanical ventilation (invasive or non-invasive)
  • Receiving antiviral therapy (any medication at any dose and for any intended duration) for < 72 hours
  • Clinicians must have a 'moderate', 'high' or 'moderate to high' index of suspicion for H1N1

Exclusion Criteria:

  • Age < 16 years
  • Do not resuscitate or re-intubate order documented on chart or anticipated withdrawal of life support
  • Weight < 40 kg
  • Unable to receive or unlikely to absorb enteral study drug (e.g. incomplete or complete bowel obstruction, intestinal ischemia, infarction, short bowel syndrome)
  • Rosuvastatin specific exclusions:

    1. Already receiving a statin (Atorvastatin, Lovastatin, Simvastatin, Pravastatin, Rosuvastatin)
    2. Allergy or intolerance to statins
    3. Receiving niacin, fenofibrate, cyclosporine, gemfibrozil, lopinavir, ritonavir or planned use of oral contraceptives or estrogen therapy during the ICU stay
    4. CK exceeds 10 times ULN or ALT exceeds 8 times the ULN
  • Severe chronic liver disease (Child-Pugh Score 11-15) (see Appendix 6)
  • Previous enrolment in this trial
  • Pregnancy or breast feeding
  • At the time of enrolment, patients must not have received >72 hours of antiviral therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01798602

Layout table for location information
Canada, Ontario
St. Michael's Hospital
Toronto, Ontario, Canada, M5B 1W8
Sponsors and Collaborators
Canadian Critical Care Trials Group
Canadian Institutes of Health Research (CIHR)
The Physicians' Services Incorporated Foundation
Public Health Agency of Canada (PHAC)
Additional Information:
Layout table for additonal information
Responsible Party: Canadian Critical Care Trials Group Identifier: NCT01798602    
Other Study ID Numbers: CCCTG
First Posted: February 26, 2013    Key Record Dates
Last Update Posted: February 26, 2013
Last Verified: February 2013
Keywords provided by Canadian Critical Care Trials Group:
Additional relevant MeSH terms:
Layout table for MeSH terms
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors